Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in ...

Amgen said on Monday its experimental cancer therapy significantly improved overall survival in patients with advanced ...

M.D., executive vice president of Research and Development at Amgen. "These first positive top-line results of an FGFR2b targeted monoclonal antibody from our Phase 3 FORTITUDE-101 study mark a ...

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab, which achieved significant ...

Amgen announced the phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) ... (G/GEJ) cancer with FGFR2b overexpression and who are non-HER2 positive.

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab in combination with chemotherapy (mFOLFOX6), achieved its primary goal of overall survival (OS) in ...

Amgen & Zai Lab's trial shows bemarituzumab + chemo boosts survival in gastric cancer with FGFR2b. Read more here.

Amgen said on Monday its experimental therapy helped patients with advanced gastric cancer live longer when combined with ...

amgen announces positive topline phase 3 results for bemarituzumab in fibroblast growth factor receptor 2b (fgfr2b) positive first-line gastric cancer Jun. 30, 2025 9:00 AM ET Amgen Inc. (AMGN) ...

amgen announces positive topline phase 3 results for bemarituzumab in fibroblast growth factor receptor 2b (fgfr2b) positive first-line gastric cancer Provided by PR Newswire Jun 30, 2025, 1:00:00 PM ...

Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy ... cancer with FGFR2b overexpression and who are non-HER2 positive.